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Abstract
Cytokinesis, the final phase of cell division, is necessary to form two distinct daughter cells with correct distribution of
genomic and cytoplasmic materials. Its failure provokes genetically unstable states, such as tetraploidization and
polyploidization, which can contribute to tumorigenesis. Aurora-B kinase controls multiple cytokinetic events, from
chromosome condensation to abscission when the midbody is severed. We have previously shown that HIPK2, a kinase
involved in DNA damage response and development, localizes at the midbody and contributes to abscission by
phosphorylating extrachromosomal histone H2B at Ser14. Of relevance, HIPK2-defective cells do not phosphorylate H2B
and do not successfully complete cytokinesis leading to accumulation of binucleated cells, chromosomal instability, and
increased tumorigenicity. However, how HIPK2 and H2B are recruited to the midbody during cytokinesis is still unknown.
Here, we show that regardless of their direct (H2B) and indirect (HIPK2) binding of chromosomal DNA, both H2B and
HIPK2 localize at the midbody independently of nucleic acids. Instead, by using mitotic kinase-specific inhibitors in a
spatio-temporal regulated manner, we found that Aurora-B kinase activity is required to recruit both HIPK2 and H2B to the
midbody. Molecular characterization showed that Aurora-B directly binds and phosphorylates H2B at Ser32 while indirectly
recruits HIPK2 through the central spindle components MgcRacGAP and PRC1. Thus, among different cytokinetic
functions, Aurora-B separately recruits HIPK2 and H2B to the midbody and these activities contribute to faithful
cytokinesis.
Introduction
Up to one-third of human cancers are likely to originate
through unscheduled tetraploidization, a genetically
unstable state that can promote aneuploidy and chromoso-
mal instability (CIN). Faithful cytokinesis is required to
preserve ploidy and prevent such genetically unstable state
[1–3]. Cytokinesis proceeds through different phases start-
ing from specification of the cleavage plane and ingression
of cleavage furrow, progressing to central spindle assembly
and subsequent midbody formation, ultimately ending with
abscission [4–6]. The right execution of each phase strictly
depends on the success of the previous one, thus chemical
biology approaches have been developed to spatially and
temporally probe the different phases [7].
Aurora-B is a Ser/Thr kinase that in mammals was ori-
ginally identified as a kinase overexpressed in cancers [8]
and required for cytokinesis [9]. Along with key roles in
histone H3 phosphorylation, chromosome condensation/
alignment, and spindle assembly checkpoint in mitosis,
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Aurora-B acts at different steps throughout cytokinesis [10,
11]. In a spatio-temporal manner, Aurora-B promotes the
formation of cleavage furrow, central spindle, and midbody
by phosphorylation and recruitment of motors and
microtubule-associated proteins, including the cen-
tralspindlin components MKLP1 and MgcRacGAP, the
Rho GTPase activator ECT2, and the microtubule-bundling
protein PRC1 [12–15]. Finally, when lagging chromatin is
present at midbody, Aurora-B prevents abscission through
activation of the abscission checkpoint [16, 17].
The midbody is a tightly packed antiparallel microtubule
bridge that transiently connects the daughter cells at the end
of cytokinesis. It serves as a platform to orchestrate cytos-
keleton rearrangements, plasma membrane remodeling, and
recruitment of the functional complexes needed for abscis-
sion. During its formation, several proteins relocate from
central spindle to distinct midbody domains [18]. Besides
Aurora-B, midbody assembly and function is regulated by
the mitotic kinases CDK1, PLK1, and Citron kinase, which
are crucial for localization, interaction, and enzymatic
activity of several cytokinesis factors [4]. Recently, we have
described the contribution of an additional kinase,
homeodomain-interacting protein kinase 2 (HIPK2), and its
phosphorylation target, the extrachromosomal histone H2B,
in the control of midbody abscission and in prevention of
tetraploidization and CIN [19, 20].
HIPK2 is a Tyr-regulated Ser/Thr kinase [21, 22]
involved in DNA damage response (DDR) and develop-
ment [23–25]. In interphase, HIPK2 mostly localizes at
nuclear speckles [26] and its nuclear activity is relevant for
anticancer therapy because it induces p53-dependent and
-independent apoptosis in response to cytotoxic drugs [27,
28]. Histones are the nucleosome assembly proteins; how-
ever, a few extrachromosomal activities of histones have
been described [29, 30]. In cytokinesis, HIPK2 and extra-
chromosomal histone H2B colocalize at midbody inde-
pendently of the presence of DNA, such as chromosome
bridges, lagging chromatin, or ultra-fine BLM bridges [19].
At midbody, HIPK2 phosphorylates H2B at Ser14 (H2B-
S14P) and contributes to abscission [19]. We also showed
Fig. 1 H2B and HIPK2 localize
at midbody independently of
RNA. a Representative images
of proliferating HCT116
DICER-proficient and -defective
cells analyzed for midbody
localization of histone H2B
(green; left panels) and HIPK2
(green, right panels). Midbodies
were marked with anti-β-tubulin
Ab (β-Tub, red); DNA was
visualized with Hoechst (blue).
b Schematic representation of
HeLa cells telophase enrichment
with nocodazole,
permeabilization, and treatment
with RNase A, RNase III, and
RNase H to cleave, respectively,
single-strand RNA, double-
strand RNA, and RNA/DNA
hybrid. PBS and DNase I were
used as negative controls. c
After treatment, cells were fixed
and stained with anti-β-tubulin
Ab (red) and anti-H2B (green).
DNA was marked with Hoechst
(blue). Representative images of
HeLa cells treated with the
indicated enzymes. Each
midbody visualized (n > 50 in
two independent experiments)
was positive for H2B staining.
Scale bar is 10 μm
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that H2B localizes at midbody independently of HIPK2, but
the absence of the kinase results in loss of H2B-S14P,
impaired abscission, and accumulation of tetraploid and
polyploid cells that contribute to CIN and increased
tumorigenicity [19, 20]. Of relevance, the sole expression of
a phosphomimetic H2B-S14D mutant in HIPK2-null cells
abolishes cytokinesis defects, restores cell division and
proliferation [19], and inhibits tumorigenicity [20]. These
data show that HIPK2 controls cytokinesis through extra-
chromosomal H2B-S14P and this activity is linked to
tumorigenicity. However, which are the molecular path-
ways involved in the recruitment of HIPK2 and H2B to
midbody is still unknown.
In this study, we evaluated the possible contribution of
RNA and mitotic kinases in the midbody recruitment of
HIPK2 and H2B. We found that both proteins are separately
recruited through the activity of the same kinase, Aurora-B.
Results
H2B and HIPK2 localize at the midbody
independently of RNA
Previous studies have shown that RNA is required for the
assembly of protein complexes such as the 53BP1 foci in
DDR [31]. Thus, we tested the possibility that H2B and/or
HIPK2 midbody localization might depend on the presence
of RNA. We first evaluated whether microRNAs might
contribute to midbody localization. Double immuno-
fluorescence (IF) for the midbody marker β-tubulin and
H2B or HIPK2 [19] were performed on parental HCT116
cells and their DICER-defective derivatives showing
decrease amount of microRNAs [32]. No apparent differ-
ence was detectable between the two cell types regarding
the midbody localization of both H2B and HIPK2 (Fig. 1a),
indicating that microRNAs are dispensable for this event.
To assess whether other types of RNAs might be
involved, we treated live HeLa cells with RNases adapting
the protocol from Francia and colleagues [31] (Supple-
mentary Figure S1a). We treated live cells enriched in ana-
telophase to assess midbody formation and protein locali-
zation in the presence of different types of RNases targeting
single and double-strand RNA, and RNA/DNA hybrid (Fig.
1b). As H2B and HIPK2 localize at the midbody indepen-
dently of DNA [19], DNase I treatment was used as nega-
tive control together with buffer-treated cells. As assessed
by IF, none of these treatments was able to inhibit midbody
formation or the midbody localization of H2B (Fig. 1c) and
HIPK2 (Supplementary Figure S1b), indicating that RNAs
are dispensable for their midbody recruitment.
Aurora-B kinase activity is required for midbody
localization of HIPK2 and H2B
To further investigate the mechanisms involved in HIPK2
and H2B midbody recruitment, we started with inhibiting
two of the master kinases involved in cytokinesis and
midbody formation, PLK1 and Aurora-B. To avoid early-
stage effects on central spindle formation, PLK1 and
Aurora-B were inhibited by BI 2536 and Hesperadin,
respectively, in temporally controlled modes [18, 33]
(Supplementary Figures S2a-b). In such conditions, the
inhibition of Aurora-B impairs the localization of both
Fig. 2 The kinase activity of
Aurora-B, but not of PLK1, is
required for midbody
localization of HIPK2 and H2B.
a, b Unsynchronized HeLa cells
were treated with 100 nM
Hesperadin for 80 min or with 1
µM Bi 2536 for 20 min; solvent
DMSO was used as control.
After treatment, cells were fixed
and stained with the indicated
Abs (green) in combination with
anti-β-tubulin Ab (red). DNA
was visualized with Hoechst
(blue). The percentages of
midbodies positive for the
indicated proteins were reported
as mean ± SD of three
independent experiments.
Representative images of
indicated staining at the
midbody are reported below
each chart. **p < 0.001. Scale
bar is 1 μm
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HIPK2 and H2B (Fig. 2a), whereas the block of PLK1 does
not affect the midbody recruitment of either of the two
proteins (Fig. 2b) or their colocalization with Aurora-B
(Supplementary Figure S2c). Similar results were obtained
with another Aurora-B inhibitor, the ZM-447439 (Supple-
mentary Figure S2d-f) excluding possible unspecific effects
of chemical compounds. Thus, although H2B may localize
at the midbody independently of HIPK2 [19], these data
indicate that midbody recruitment of either proteins requires
the same kinase, Aurora-B.
Aurora-B binds and phosphorylates H2B but not
HIPK2
We previously defined the midbody localization of HIPK2
and H2B-S14P also based on their colocalization with
Aurora-B [19]. To evaluate whether these colocalizations
and the recruitment activity of Aurora-B depend on its
direct interaction with HIPK2 and H2B, we performed
in vitro binding assays with purified proteins. We found that
recombinant glutathione S-transferase (GST)-Aurora-B
binds His-H2B (Fig. 3a) but does not directly interact with
GFP-HIPK2 (Fig. 3b).
Based on in silico analyses, both HIPK2 and H2B con-
tain putative Aurora-B phosphorylation consensus sequen-
ces, thus we performed in vitro kinase assays by using
Aurora-B as enzymatic source and purified HIPK2 or H2B
as substrates. As HIPK2 possess auto-phosphorylating
activity, the kinase-defective HIPK2-K228R mutant was
employed. As shown in Fig. 3c, Aurora-B phosphorylates
H2B but not HIPK2, suggesting that Aurora-B recruits
HIPK2 and H2B through different mechanisms.
Although we cannot completely exclude the possibility
that Aurora-B might directly phosphorylate HIPK2 only
after its autophosphorylation [21, 22], we know that the
kinase-defective HIPK2-K228R mutant can localize at
midbody (see below). We also observed that HIPK2 still
localizes at midbody upon depletion of extrachromosomal
H2B (LM unpublished data) indicating that midbody
Fig. 3 Aurora-B directly binds and phosphorilates H2B. a Recombi-
nant His-H2B was incubated in the presence of recombinant GST-
Aurora-B or GST alone at two different salt concentrations. Proteins
were detected by Western blotting (WB) with the indicated Abs after
GST-pull-down of two independent experiment. b GFP or GFP-
HIPK2 were incubated with recombinant GST-Aurora-B at the same
conditions described above. Proteins were detected by WB with the
indicated Abs after GFP-immunoprecipitation of two independent
experiment. c In vitro kinase assays were performed with GST-Aurora-
B, as enzymatic source, and His-H2B or GST-HIPK2-K228R as
substrates. Myelin basic protein (MBP) was used as positive control.
Proteins were separated by SDS-PAGE and radioactivity detected by
autoradiography. Coomassie stain was performed as loading control. n
= three independent experiment. White asterisks mark nonspecific
bands
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recruitment of HIPK2 is independent of H2B, further sup-
porting the separate recruitment of the two proteins.
Aurora-B phosphorylates H2B at Ser32
H2B contains nine putative Aurora-B phosphorylation sites.
In order to identify specific phosphorylation site/s, we
analyzed by mass spectrometry (MS) a recombinant His-
H2B protein that had been phosphorylated in vitro by
Aurora-B. On a total of 126 amino acids, we were able to
properly map the H2B region downstream amino acid 35,
where, however, we could not detect any phosphorylated
Ser or Thr residues (Supplementary Figure S3a). Unfortu-
nately, the N-terminal region encompassing amino acids
1–35 could not be resolved, despite the employment of
several cleavage patterns, probably due to the presence of a
high positive charge. Nonetheless, H2B-Ser32 phosphor-
ylation (H2B-Ser32P) has been already reported and a
validated anti-p-Histone H2B-S32 Ab is commercially
available [34]. Immunoblot analyses of cold kinase assays
performed with recombinant His-H2B and GST-Aurora-B
Fig. 4 Aurora-B phosphorylates H2B at Ser32. a Cold in vitro kinase
assays were performed and H2B-S32P detected using anti-p-Histone
H2B-Ser32 Ab. Ponceau staining and immunoblot with anti-H2B Ab
were used as loading controls. n= three independent experiment. b
Unsynchronized HeLa cells were treated with Hesperadin or DMSO
for 80 min and stained with anti-p-Histone H2B-S32 and anti-β-tubulin
Abs. Hoechst was used to stain DNA (blue). Representative images of
cells at telophase stage are reported. Scale bar is 5 μm. c Repre-
sentative confocal images of HeLa cells at indicated stages of mitosis
and cytokinesis showing colocalization between H2B-S32P (green)
and Aurora-B (red) n= four independent experiment. DNA was
stained with Red-Dot2 far-red (pseudo-colored blue); scale bar is 10
μm. d, e HeLa cells stably expressing GFP-H2B WT or its derivative
GFP-H2B-S32A at passage two after the establishment of stable
populations (i.e., 15 days after blastacidin treatment) were enriched in
telophase and protein lysates were obtained from TCEs (T-TCE) or
after midbody isolation (MI). Untrasfected HeLa cells were used as
negative control. The indicated proteins were analyzed by WB.
Immunoblots with anti-PRC1 and anti-p-Histone H2B-S14 Abs were
used as positive control to verify the quality of midbody isolation.
Immunoblot with anti-PCNA Ab was used as control to evaluate
nuclear contamination. Representative WBs are shown. In d, samples
were loaded on the same gel and processed on the same filter. Blot was
vertically cropped to eliminate non-related samples
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using this Ab showed that Aurora-B is indeed able to
phosphorylate H2B-Ser32 in vitro (Fig. 4a).
Next, we verified the specificity of this anti-p-Histone
H2B-S32 Ab in IF by using HeLa cells treated with
Hesperadin to impair H2B midbody recruitment (Fig. 2a). A
clear immunostaining was detected in the midbodies of
control cells while no fluorescence was present in
Hesperadin-treated cells (Fig. 4b) attesting the specificity of
this immunostaining. Therefore, we analyzed the localiza-
tion of H2B-Ser32P and its relationship with Aurora-B. We
found a clear H2B-Ser32P signal already in anaphase A that
persists and colocalizes with Aurora-B throughout
cytokinesis (Fig. 4c, Supplementary Figure S3b). Of rele-
vance, this phosphorylation was not detectable on nucleo-
somal H2B belonging to chromosome bridges
(Supplementary Figure S3c), supporting a role of extra-
chromosomal H2B-Ser32P in cytokinesis progression rather
than in cytokinesis checkpoint.
Finally, we evaluated whether the Aurora-B-mediated
phosphorylation of H2B-Ser32 is essential for H2B mid-
body recruitment. HeLa cells were transfected with a GFP-
tagged wild-type H2B or with a non-phosphorylatable GFP-
H2B-S32A mutant form. Similarly to wild-type H2B, the
non-phosphorylatable H2B-S32A was present in telophase
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and midbody extracts (Fig. 4d). To exclude a possible
contribution from contaminating nucleosomes, immuno-
blots were reacted with anti-p-Histone H2B-S14 Ab that, in
the absence of apoptosis, specifically detects midbody-
localized H2B [19] (Supplementary Figure S3d). Also in
this condition, the H2B-S32A mutant was detected at
midbody (Fig. 4e) indicating that S32 phosphorylation is
dispensable for H2B recruitment.
Taken together, these data indicate that Aurora-B phos-
phorylates H2B at Ser32 and H2B-Ser32P detection in
mitosis follows Aurora-B and persists throughout cytokin-
esis. However, these data also indicate that additional
Aurora-B-dependent event/s, besides phosphorylation on
S32, are required for H2B recruitment.
HIPK2 is recruited to midbody via Aurora-B-
regulated central spindle components
To get clues on the mechanism of Aurora-B-dependent
recruitment of HIPK2 to midbody, we compared the sub-
cellular distribution of HIPK2 full-length (FL) with a series
of tag-HIPK2 mutants. Together with HIPK2 deletion
forms, we tested a few point mutants including the tumor-
associated N958I and R868W mutants, which have been
shown to possess a reduced p53 activation capacity [35], the
kinase-defective K228R [36, 37], the sumoylation-resistant
K32A [38], the ubiquitylation-resistant K1189R [39], and
the non-acetylatable K835R [40]. These experiments show
that only the region encompassing amino acids 846–1002 of
HIPK2, including the speckle retention signal (SRS), is
necessary for midbody localization. In contrast, all the other
mutants containing this region retain the capacity to localize
at midbody (Fig. 5a), although its structure was slight
altered (long, stretched bridges) by overexpression of each
HIPK2-carrying vector, suggesting a mild toxic effect
independent of the type of mutation.
The SRS region of HIPK2 is required for the physical
interactions with many of its targets; [23] thus, we looked
for cytokinesis factors that might interact with HIPK2. In
order to enrich for cytokinesis factors, total cell extracts
(TCEs) were obtained from telophase-synchronized HeLa
cells and employed in GST-pull-down assay using purified
GST-HIPK2(FL) (Fig. 5b). Such experiment confirmed that
Aurora-B does not interact with HIPK2 (Fig. 5c, upper
lane). In addition, we observed that abscission proteins
(e.g., CEP55, TSG101, ALIX) that reach the midbody later
in cytokinesis do not interact with HIPK2 (Fig. 5c, lower
lanes). In contrast, MgcRacGAP and PRC1, two key factors
in central spindle assembly [13, 14], are reproducibly pre-
sent in the GST-HIPK2(FL) pull-downs (Fig. 5c, middle
lanes) but not in the control GST.
Interestingly, Aurora-B indirectly regulates MgcRacGAP
and PRC1 recruitment via their kinesin partners [14, 15].
However, depletion of MgcRacGAP or PRC1, or inhibition
of their interaction, has been shown to deeply affect mid-
body formation [41, 42]. Therefore, to unveil a possible role
of MgcRacGAP and/or PRC1 in the midbody recruitment of
HIPK2, we followed indirect approaches.
First, we asked whether the HIPK2 region involved in
midbody localization is also required for binding to central
spindle proteins. As shown by GST-pull-down assays (Fig.
5d), the HIPK2 deletion mutant (1–845), lacking the C-
terminal region necessary for midbody recruitment, is
actually unable to bind MgcRacGAP and PRC1, suggesting
a relationship between midbody localization and interaction
with these central spindle factors.
Second, we assessed whether HIPK2 colocalizes with
MgcRacGAP and PRC1 at midbody. Double IF analyses of
early and late telophase showed that HIPK2 partially
colocalize with the two central spindle factors (Supple-
mentary Figure S4).
Third, we asked whether the Hesperadin-induced inhi-
bition of HIPK2 midbody recruitment is also associated
with inhibition of MgcRacGAP and PRC1 midbody
Fig. 5 SRS region is essential for HIPK2 midbody localization and
interaction with PRC1 and MgcRacGAP central spindle factors. a
HeLa cells were transfected with vectors expressing tagged HIPK2-FL
or relative derivative mutants. Numbers are referred to the current
NCBI RefSeq of HIPK2 (NP_073577.3 and NP_034563.2). Cells
were analyzed 24 h post-transfection by IF performed with anti-β-
tubulin Ab to mark midbodies (red) in combination with opportune
anti-tag Abs to visualize midbody localization of tagged HIPK2 forms.
GFP-tagged proteins were visualized by autofluorescence. Midbodies
of transfected cells were analyzed for the presence of tagged HIPK2 or
relative mutants at the midbody in two independent experiments. Here
reported is a schematic representation of the analyzed HIPK2 con-
structs with their localization at the midbody. Plus (+) indicates
midbody localization in >90% of the cells; minus (−) indicates mid-
body localization in <5% of the cells. Left panel: schematic repre-
sentation of HIPK2-FL with its domains (HID homeobox Interacting
domain, SRS region containing speckle retention sequence, AID auto-
inhibitory domain) and its deletion or point mutant forms. Right
panels: representative images of midbodies with or without the indi-
cated GFP-HIPK2 forms. Scale bar is 2 μm. b, c GST-HIPK2 and GST
alone were produced in H1299 cells, purified by GST pull-down,
analyzed by WB b and incubated with an equal amount of T-TCE
(0.6 mg) obtained as in Fig. 4d. Proteins bound to GST-HIPK2 and
GST were pulled-down and analyzed by WB with the indicated Abs.
Representative WBs are shown c; input corresponds to 0.3% of T-
TCE. d T-TCE from HeLa cells were obtained and incubated with the
indicated GST-fusion proteins as in b,c. The presence of the indicated
cytokinetic proteins was assessed by WB. Representative WBs are
shown. Input corresponds to 0.3% of the T-TCE. e HeLa cells were
treated with Hesperadin as in the Fig. 2. At least 100 midbodies for
each condition have been scored and the percentages of midbodies
with the indicated localization (i.e., normal, broad, and lost) are
reported as mean ± SD of two independent experiments. *p < 0.05. f
HeLa cells were transfected with HIPK2-specific stealth siRNAs (H-i)
or negative control siRNA (C-i), fixed 4 days after transfection and
analyzed by IF with anti-β-tubulin in combination with Abs against the
indicated proteins. Scale bar is 1 μm
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localization. As shown in Fig. 5e, in the presence of
Hesperadin the midbody localization of MgcRacGAP is
strongly impaired and that of PRC1 is significantly affected,
further supporting a correlation among these events. Thus,
we evaluated whether the inhibition of HIPK2 midbody
localization is consequent to or concomitant with that of
MgcRacGAP and/or PRC1. To this aim, we assessed the
midbody localization of the central spindle components
upon HIPK2-specific RNA interference. As expected,
HIPK2 depletion inhibits H2B-S14P at midbody. However,
we could not observe any alteration in the localization of
MgcRacGAP, PRC1, and Aurora-B (Fig. 5f), indicating that
HIPK2 recruitment temporally follows that of central
spindle factors.
Taken together, these results suggest that Aurora-B
indirectly recruits HIPK2 to the midbody through
MgcRacGAP and PRC1.
Impairment of Aurora-B-mediated activities on
HIPK2 and H2B induces cytokinesis failure
We previously reported that HIPK2 depletion results in the
loss of H2B-S14P at midbody and in the accumulation of
binucleated cells due to cytokinesis failure [19]. Analogous
readouts are induced by Aurora-B inactivation [43].
Therefore, we asked whether the impairment of Aurora-B-
mediated activities on HIPK2 and/or H2B might induce
cytokinesis failure.
Fig. 6 Impairment of Aurora-B-mediated activities on H2B and
HIPK2 induces cytokinesis failure. a, b HeLa cells were transfected
with vectors carrying the indicated GFP-HIPK2 forms and stained 24 h
post-transfection with anti-p-Histone H2B-S14 and Hoechst. The
percentages of midbodies positive for H2B-S14P staining in the
transfected populations a and the percentages of binucleated cells also
in the transfected populations b are reported as mean ± SD of two
different experiments. c HF were transfected with vectors carrying
GFP-tagged H2B-WT or the non-phosphorylatable H2B-S32A deri-
vative. Cells were stained with anti-β-tubulin Ab and Hoechst. The
percentages of binucleated cells in the GFP-positive populations were
evaluated at the indicated time-points post-transfection and reported as
fold change relative to that of GFP-H2B-WT in two different experi-
ments. *p < 0.05 and **p < 0.001 unpaired t-test. d HeLa cells were
transfected with the same vectors as in b and treated with blastacidin
48 h after transfection to select stable transfected cells. The percentage
of GFP-positive cells at 2 days (p0) after transfection, or 21 and
39 days after transfection (i.e., at the 3rd and 9th culture passage after
blastacidin selection) is reported as mean ± SD of two different
experiments. *p < 0.05 unpaired t-test, comparison between percen-
tages of H2B-WT- and H2B-S32A-positive cells at each passage. e
Schematic representation of Aurora-B activities on HIPK2 and H2B in
cytokinesis. Aurora-B indirectly recruits HIPK2 via MgcRacGAP and
PRC1 and directly phosphorylates H2B at Ser32. Additional Aurora-
B-dependent event/s, besides phosphorylation on S32, are required for
H2B recruitment. Dashed lines indicate still unknown mechanism/s.
Phosphorylation of histone H2B at Ser32 by Aurora-B and Ser14 by
HIPK2 contribute the successful cytokinesis
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We inhibited midbody recruitment of the endogenous
HIPK2 by sequestering its interactors, MgcRacGAP and
PRC1. To this aim, HeLa cells were transfected with GFP-
HIPK2(791–1196), the minimal C-terminal portion that still
localizes at midbody (Fig. 5a), contains the region required
to bind MgcRacGAP and PRC1, but lacks the kinase
domain required to phosphorylate H2B at Ser14 and pro-
mote abscission [19]. We cannot directly demonstrate the
absence of endogenous HIPK2 at midbody because anti-
HIPK2 Abs recognize also the exogenous derivatives.
However, we found that compared with HIPK2(FL), HIPK2
(791–1196)-expressing cells have impaired ability to
phosphorylate H2B-Ser14 (Fig. 6a) and perform successful
cytokinesis, as shown by accumulation of binucleated cells
(Fig. 6b).
Next, we assessed whether GFP-H2B-S32A, which
cannot be phosphorylated by Aurora-B but can still localize
at midbody, has functional consequences on cytokinesis.
Compared with wild-type H2B, which does not induce
significant effects and can be expressed for extended time,
transfection of H2B-S32A resulted in accumulation of
binucleated cells in human fibroblasts (HFs; Fig. 6c) and in
the loss of H2B-S32A expression after a few passages in
HeLa cells (Fig. 6d).
Overall, these results support a role for Aurora-B-
mediated activities on HIPK2 and H2B midbody recruit-
ment and in their contribution to faithful cytokinesis.
Discussion
HIPK2 works as a haploinsufficient tumor suppressor and
its inactivation increases tumorigenicity [44]. The tumor-
suppressing activities of HIPK2 have been linked to cell
protection against genome instability induced by different
types of genotoxic stress, to inhibition of tumor invasion,
multidrug resistance, and angiogenesis in hypoxia, and,
more recently, to prevention of CIN as consequence of
cytokinesis failure. While most of these activities depend on
the nuclear functions of HIPK2 [44, 45], prevention of CIN
relies, at least in part, on the midbody localization of HIPK2
and its target H2B, and their role in abscission for faithful
cytokinesis [19, 20].
In this study, we investigated how HIPK2 and extra-
chromosomal histone H2B are recruited to the midbody.
Stimulated by the recent observations that microRNAs can
be involved in the formation of specific protein complexes
[31], we asked whether RNA might be responsible for H2B
or HIPK2 cytokinesis recruitment. We tested whether
microRNA, single-strand RNA, double-strand RNA, or
RNA/DNA hybrid might contribute to midbody recruitment
of H2B or HIPK2. However, despite the good quality of our
positive controls, we did not observe any defects in H2B or
HIPK2 midbody localization, supporting the conclusion that
nucleic acids are not involved in the cytokinetic distribution
of the kinase and its histone target. Instead, we found that
Aurora-B, one of the key mitotic kinases, is needed for the
recruitment of both HIPK2 and H2B via two separate
mechanisms (Fig. 6e).
Together with PLK1 and CDK1, Aurora-B is a key
regulator of cell division. Aurora-B, as a component of the
chromosomal passenger complex, localizes to the conden-
sing chromosomes in prophase until the midbody in telo-
phase, passing through the centromeres in metaphase and
the central spindle in anaphase [11, 46]. Consistent with its
spatio-temporal localization, Aurora-B regulates different
mitotic and cytokinetic events promoting or delaying their
progression, depending on specific events. Hence, Aurora-B
kinase activity promotes chromosome condensation in
mitosis and central spindle and midbody formation in
cytokinesis. On the other side, Aurora-B inhibits mitosis
progression to anaphase until all sister chromatid pairs are
properly oriented (i.e., the spindle assembly checkpoint)
and prevents abscission in cytokinesis when DNA remains
at the cleavage site (i.e., the abscission checkpoint). Here,
we found that Aurora-B directly binds and phosphorylates
histone H2B at Ser32 in vitro. We observed that H2B-
Ser32P colocalizes with Aurora-B at the central spindle in
anaphase A and persist throughout the subsequent steps,
until abscission. Of relevance, this behavior was detectable
at each cytokinesis and was independent from the presence
of aberrant DNA at the cleavage plane, thus indicating that
H2B-Ser32 phosphorylation by Aurora-B promotes, rather
than delays, cell division. In addition, our results indicate
that histone H2B is temporally recruited for cytokinesis
before HIPK2 and this is consistent with the observation
that H2B is present at the midbody also in Hipk2-/- MEFs
[19].
As assessed by IF with anti-histone H2B Ab that
recognizes the histone independently of its posttranslational
modifications, inhibition of Aurora-B kinase activity by
Hesperadin or ZM-447439 blocks H2B recruitment. How-
ever, the expression of a non-phosphorylatable H2B-S32A
mutant showed that Ser32 phosphorylation is dispensable
for H2B recruitment because the mutant can still localize at
midbody and be phosphorylated at Ser14 by HIPK2. Taken
together, these results suggest that other Aurora-B-
dependent activities are necessary for the recruitment of
H2B. Indeed, based on the complex network of interactions
among the microtubule modulators and their regulators
during the assembly of the central spindle and midbody
[13], this result is not particularly surprising. However, as
discussed below, H2B-Ser32P is functionally required for
faithful cytokinesis.
We obtained direct and indirect evidence suggesting that
HIPK2 is recruited to the midbody through the Aurora-B-
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regulated central spindle factors MgcRacGAP and PRC1.
Of relevance, during cytokinesis, HIPK2/PRC1 colocaliza-
tion was previously reported by Hofmann et al. [45]. An
important test for the functional significance of these
interactions would have been the evaluation of localization
epistasis. However, the key role of PRC1 and cen-
tralspindlin as hub factors limited our analyses to the eva-
luation of the proper localization of central spindle factors
upon depletion of HIPK2, while the opposite (PRC1 or
MgcRacGAP depletion) could not be informative for
HIPK2 midbody localization [41, 42]. At this point, we do
not know whether there is a direct binding between HIPK2
and central spindle factors. However, we showed that the
HIPK2 region required for interaction with MgcRacGAP
and PRC1 (the SRS containing region) is also required for
midbody localization. Interestingly, the SRS region, besides
mediating the interactions with most of the non-homeotic
factors, is also involved in the subnuclear localization of
HIPK2 into speckled structures [23, 47].
HIPK2 activity and stability are controlled by different
posttranslational modifications [48]. We previously showed
that the kinase-defective HIPK2-K228R mutant, which is
largely hypophosphorylated [21, 22], is still able to localize
at the midbody but it is not able to phosphorylate H2B and
does not rescue the abscission failure in Hipk2-/- MEFs
[19]. Here, we confirmed this observation and extended the
analysis to other posttranslational modification-defective
mutants, including sumoylation-defective, acetylation-
defective, ubiquitylation-resistant, and tumor-associated
point mutants. All of these mutants retain the ability to
localize at midbody indicating that the posttranslational
modifications relevant for HIPK2 activity in stressing con-
ditions are dispensable for the localization at midbody
during cytokinesis. Altogether, these results support the
conclusion that, in contrast to stressing conditions, the
recruitment at midbody of HIPK2 depends on protein/pro-
tein interactions rather than posttranslational modifications.
Aurora-B is frequently overexpressed in human cancers
and several small molecule inhibitors have been developed
and tested in preclinical studies and clinical trials [49, 50].
Consistent with the spatio-temporal localization of Aurora-
B, these inhibitors mainly act in mitosis by silencing the
spindle assembly checkpoint and leading to chromosome
missegregation, cytokinesis failure, and polyploidization
[51, 52]. Aurora-B overexpressing tumor cells are particu-
larly sensitive to these effects and eventually undergo cell
death. However, proliferating normal cells are also sig-
nificantly affected resulting in meaningful clinical toxicity
[53]. It has been shown that targeting mitotic exit without
affecting the spindle assembly checkpoint might have a
larger therapeutic window [54]. Yet, such effect cannot be
obtained by directly inhibiting the kinase activity of Aurora-
B. Thus, a block of the interactions with its cytokinesis
partners has been proposed [55]. Here, we show that among
different cytokinesis functions, Aurora-B separately recruits
HIPK2 and H2B to the midbody and doing so contributes to
faithful cytokinesis. Indeed, inhibition of these Aurora-B
recruitment activities, by expressing the non-
phosphorylatable H2B-S32A mutant or the minimal C-
terminal portion of HIPK2 that binds and sequesters
MgcRacGAP and PRC1, results in accumulation of binu-
cleated cells. These data confirm a key role for HIPK2 and
H2B in cytokinesis and offer the possibility of testing
HIPK2 and extrachromosomal histone H2B as therapeutic
targets for inhibition of cell division.
Materials and methods
Cell culture and reagents
HeLa (kind gift of C. Passananti), H1299 (kind gift of G.
Blandino), U2OS (kind gift of F. Moretti), hTERT-
immortalized HF [56], HCT116 parental or DICER-defec-
tive (kind gift of B. Vogelstein) were cultured at 37 °C and
5% CO2 in Dulbecco’s modified Eagle’s medium Gluta-
MAX supplemented with 10% fetal bovine serum, peni-
cillin/streptomycin (Life Technologies) and routinely tested
for mycoplasma contamination. Cells were transfected
using Lipofectamine LTX and PLUS reagent for plasmid
DNA and RNAiMAX for small interfering RNAs (siRNAs;
Life Technologies). HIPK2-specific RNA interference was
performed as described [19]. Kinase inhibitor treatments
were performed on unsynchronized, proliferating cells.
Hesperadin (Selleckchem) and ZM-447439 (Signalchem)
were used to inhibit Aurora-B and Bi 2536 (AbMole) to
inhibit PLK1. Solvent dimethylsulfoxide (DMSO; Sigma-
Aldrich) was used as control.
Enrichment in telophase, midbody isolation, and
RNase treatments
HeLa cells were enriched in telophase by treatment with
nocodazole (Sigma-Aldrich; 100 ng/ml for 4 h) followed by
mitotic shake-off and nocodazole wash out. Collected cells
were plated on poly-L-lysine-coated coverslips and incu-
bated to reach different cytokinesis stages. Midbodies were
isolated as described [19, 57] and extracted in buffer
(50 mM Tris-HCl pH 7.4, 600 mM NaCl, 0.1% sodium
dodecyl sulfate (SDS), 0.5% NP40, 1 mM DTT, 5 mM
EDTA) supplemented with protease- and phosphatase-
inhibitor mix (Roche).
In vivo RNase A treatment was adapted from Francia
et al. [31]. HeLa cells were plated onto poly-L-lysine-coated
coverslips and UVB irradiated. One hour later, cells were
permeabilized with increasing percentage of Tween20 (0.5,
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0.75, 1, 1.5 or 2%) in phosphate-buffered saline (PBS) for
10 min at room temperature (RT). RNase A treatment was
carried with 1 mg/ml ribonuclease A from bovine pancreas
(Roche) in PBS for 25 min at RT; PBS alone or was used as
control. Next, cells were fixed in 2% formaldehyde and
immunoreacted with anti-53BP1 Ab (Abcam). Mitotic
enriched HeLa cells (45 min post-nocodazole wash out)
were permeabilized with 0.75% Tween20 and treated with
PBS, RNase A (Roche), RNase III (25U; Ambion), RNase
H (25U, Ambion), or DNase I (25U; Ambion), fixed with
2% formaldehyde for 10 min or cold methanol 100% for
5 min at −20 °C.
Western blotting
TCEs were prepared in lysis buffer (50 mM Tris-HCl pH
8.0, 150 mM NaCl, 0.5% sodium-deoxycholate, 0.1% SDS,
1% NP40 and 1 mM EDTA) supplemented with protease
inhibitor mix (Roche) and Halt Phosphatase Inhibitor
Cocktail (Life Technologies). Proteins were resolved by
SDS-polyacrylamide gel electrophoresis (PAGE) using
NuPAGE® Novex Bis-Tris Gels (Life Technologies),
transferred onto nitrocellulose membranes (Bio-Rad), and
analyzed with the required Abs. Horseradish peroxidase
(HRP)-conjugated goat anti-mouse and anti-rabbit second-
ary Abs (Bio-Rad) were used. Immunoreactivity was
determined by ECL-chemioluminescence reaction (Amer-
sham). The following Abs were employed: anti-TSG101,
anti-cep55, anti-MgcRacGAP1, anti-p-histone-H2B-S32,
and anti-Aurora-B (Abcam); anti-PRC1, anti-Alix, anti-
PCNA, and anti-GST (Santa Cruz); anti-GFP (Roche); anti-
p-histone-H2B-S14 (Cell Signaling).
IF microscopy
Cells were seeded onto poly-L-lysine-coated coverslips,
fixed in ice-cold methanol or 2% formaldehyde, washed
three times in PBS, permeabilized in 0.25% Triton X-100 in
PBS for 10 min, blocked in 0.2% Triton X-100, 5% bovine
serum albumin in PBS for 60 min before the required pri-
mary Abs were applied. The following Abs were employed:
anti-Aurora-B (BD-Bioscience); anti-ECT2, anti-PRC1,
anti-MKLP1, and anti-PLK1 (Santa Cruz); anti-HIPK2
(rabbit polyclonal Ab [19]); anti-p-histone-H2B-S14 (Cell
Signaling); anti-p-histone-H2B-S32, anti-H2B, anti-53BP1,
and anti-MgcRacGAP1 (Abcam); anti-β-tubulin-Cy3 and
anti-α-tubulin-FITC (Sigma-Aldrich); secondary 488- or
594-conjugated Abs (Life Technologies). DNA was marked
with Hoechst 33342 (Sigma-Aldrich) or Red-Dot2 far-red
(Biotium). Cells were examined under an Olympus BX53
microscope using a cooled camera device (ProgRes MF)
and with confocal microscope Zeiss LSM510-Meta.
Expression vectors and recombinant proteins
The following expression vectors were employed: pEGFP-
c2, pEGFP-HIPK2-FL and its derivative deletion and point
mutants pEGFP-HIPK2-1-633; pEGFPHIPK2-1-845;
pEGFP-HIPK2-delta846-1002; pEGFP-HIPK2-791-1196;
pEGFP-HIPK2-K228R, pEGFP-HIPK2-K1189R [39];
pLUCX-HA-HIPK2-R868W and pLUCX-HA-HIPK2-
N958I [35] kind gift of I. Kitabaiashi; pcDNA3-Flag-
HIPK2-K32 and pcDNA3-Flag-HIPK2-K835R [40] kind
gift of L.M. Schmidtz, pBOS-GFP-H2B (BD PharMingen).
pBOS-GFP-H2B-S32A mutant was obtained by site-
directed mutagenesis using QuickChange kit (Stratagene)
and analyzed by sequencing. To gain high levels of GST,
GST-HIPK2-FL or its derivatives, H1299 cells were
infected with vTF7-3 followed by transfection with
pcDNA3-eGST, pcDNA3eGST-HIPK2 or its derivatives, as
described [22]. Recombinant GFP and GFP-HIPK2 were
produced in U2OS cells by transfection of pEGFP-c2 or
pEGFP-HIPK2, as described [58]. GST-Aurora-B (A2108)
and MBP (M1891) are from Sigma-Aldrich, His-H2B
(Ag7811) from Proteintech.
GST pull-down and binding assay
GST-fusion proteins were purified from TCEs using
Glutathione-Sepharose 4 Fast Flow (GE Healthcare), incu-
bated for 2 h at 4 °C with glutathione sepharose beads,
pulled-down, washed three times with nondenaturing lysis
buffer, and used as bait in binding assays. For H2B and
Aurora-B binding assays, GST-fusion proteins were incu-
bated with 500 ng of recombinant His-H2B (Proteintech) in
50 mM Tris-HCl pH 7.5 at two salt concentrations, 150 and
250 mM NaCl. For T-TCE binding assays, GST-fusion
proteins were incubated with 0.6 mg of T-TCE in binding
buffer (50 mM Tris-HCl pH 7.5, 200 mM NaCl, 0.5%
NP40). For HIPK2 and Aurora-B binding assays, GFP or
GFP-HIPK2 were purified as described [58]. TCEs were
prepared 24 h post-transfection of U2OS cells. Supernatants
obtained after TCE centrifugations were incubated over-
night with anti-GFP Ab-sepharose beads (Abcam) at 4 °C.
GFP-proteins were incubated with GST-Aurora-B in
50 mM Tris-HCl pH 7.5 at two salt concentrations (150 and
250 mM NaCl). Bound proteins were analyzed by WB.
Kinase assay and mass spectrometry
Kinase assays were performed incubating 150 ng of GST-
Aurora-B in kinase buffer (Hepes 20 mM pH 7.5, 1 mM
DTT, 10 mMMgCl2 and 1 mM EGTA) in the presence of γ-
32P-ATP (Perlkin-Elmer, BLU502Z250UC) at 30 °C for
30 min. MBP, His-H2B, or GST-HIPK2-K228R were used
as substrates. GST-HIPK2-K228R alone was used to
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evaluate the autophosphorylation level of the defective
mutant. Proteins were resolved by SDS-PAGE and phos-
phorylation analyzed by autoradiography.
Cold kinase assays were performed with 2 μM ATP
(Roche) for 1 h and phosphorylated H2B analyzed by WB
or MS. For MS, H2B was in-gel digested with trypsin,
chymotrypsin, AspN or GluC and peptides analyzed by
liquid chromatography MS using an Ultimate 3000 HPLC
(DIONEX) connected on line with a linear Ion Trap (LTQ,
Thermo). MS/MS and MS/MS/MS were acquired in order
to search for phosphopeptides carrying mass increase and
neutral losses, respectively. Tandem mass spectra were
analyzed by Proteome Discoverer software (version 1.4,
Thermo Electron) searching.
Statistics
All data are presented as mean ±S.D. (standard deviation).
The p-values were derived from unpaired two-tailed t-tests
using GraphPad Prism software. The p-values < 0.05 were
considered significant. In all, 80 midbodies and 1000 cells
for each condition were scored, unless otherwise stated.
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